Selected Articles
| The following is a selected list of articles published by The Zucker Hillside Hospital researchers. To obtain information regarding copies of articles contact the Division of Psychiatry Research or the authors. |
Burdick KE, Hodgkinson CA, Szeszko PR, Lencz T, Ekholm JM, Kane JM, Goldman D, Malhotra AK DISC1 and neurocognitive function in schizophrenia. Neuroreport. 2005 Aug 22;16(12):1399-402. Cornblatt BA, Auther AM. Treating early psychosis: who, what, and when? Dialogues.Clin.Neurosci. 2005 7, 39-49. Cornblatt BA, Lencz T, Smith CW, Auther A. Treatment of the schizophrenia prodrome. In W.S.Stone, S. V. Faraone, & M. T. Tsuang (Eds.), Early clinical intervention and prevention of schizophrenia. Totowa, NJ: Humana Press, 2003. Cornblatt BA, Heinssen RK, Cannon TD, Lencz T. Editors Introduction: New frontiers in prodromal research. Schizophr Bull. 2003 29, 621-624. Cornblatt BA Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophr Bull. 2003 29, 633-651. Correll CU, Kane JM. The psychotic prodrome: How effective are early interventions? Advances in Schizophrenia and Clinical Psychiatry. 2004; 1,1: 2-10. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America. 2006; 15; 177-206. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-gerneration antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004 Mar;161(3):414-25. Correll CU, Lencz T, Smith CW, Auther AM, Nakayama EY, Hovey L, Olsen R, Shah M, Foley C, Cornblatt BA. Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. J Child Adolesc Psychopharmacol. 2005 Jun;15(3):418-33. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003 Nov;160(11):2063-5. Correll CU. Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? J Clin Psychiatry. 2005 Oct;66(10):1331-1332. Correll CU. Real-life dosing with second-generation antipsychotics. J Clin Psychiatry. 2005 Dec;66(12):1610- Correl CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004 Aug;174(4):477-89. Epub 2004 Jul 8. Review. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004 Aug;174(4):477-89. Epub 2004 Jul 8. Review. Funke B, Malhotra AK, Finn CT, Plocik AM, Lake SL, Lencz T, DeRosse P, Kane JM, Kucherlapati R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct. 2005 Oct 18;1:19. Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, Kucherlapati R, Malhotra AK. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet. 2004 Nov;75(5):891-8. Epub 2004 Sep 10. Goldberg JF, Burdick KE, Endick CJ. Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizer for Treatment-Resistant Bipolar Depression. Am J Psychiatry. 2004 Mar;161(3):564-6. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK. Disrupted in schizophrenia 1 (DISC1): Association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet. 2004 Nov;75(5):862-72. Epub 2004 Sep 22. Jaeger J, Berns SM, Czobor P. The Multidimensional scale of independent functioning: A new instrument for measuring functional disability in psychiatric populations. Schizophr Bull. 2003;29(1):153-68 Jaeger J, Czobor P, Berns SM. Basic neuropsychological dimensions in schizophrenia. Schizophr Res. 2003 Dec 15;65(2-3):105-16. Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry. 2001 Dec;40(12):1448-56. Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1038-45. Kafantaris V, Dicker R, Coletti DJ, Kane JM. Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol. 2001 Winter;11(4):409-13. Kane JM, Quitkin F, Rifkin A, Ramos-Lorenzi JR, Nayak DV: Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry 39:70-73, 1982. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DV, Howard A: Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness. Arch Gen Psychiatry 39:1065-1069, 1982. Kane JM, Quitkin F, Rifkin A, Wegner J, Rosenberg G, Borenstein M: Attitudinal changes following treatment in the involuntarily committed psychiatric patient. Arch Gen Psychiatry 40:374-377, 1983. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J: Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 40:893-896, 1983. Kane J, Honigfeld G, Singer J, Meltzer H & the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45:789-796, 1988. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19(2):287-302, 1993. Kane JM, McGlashan TH: Treatment of schizophrenia. Lancet 346:820-825, 1995. Kane JM: Schizophrenia. N Engl J Med 334(1):34-41, 1996. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, Borenstein M, McMenniman M: Clozapine and haloperidol in moderately refractory schizophrenia: a six-month randomized and double-blind comparison. Arch Gen Psychiatry. 58:965-972, 2001. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry. 159(4): 554-560, 2002. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. 63(9): 763-771, 2002. Kane JM, Keith S, Eerdekens M, Lindenmayer JP, Karcher K, Lesem M. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 160:1125-1132, 2003. Kane JM, Krystal J, Correll CU. Treatment models and designs for intervention research during the psychotic prodrome. Schiz Bulletin 29 (4): 747-56, 2003. Lencz T, Bilder RM, Turkel E, Goldman RS, Robinson D, Kane JM, Lieberman JA. Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Arch Gen Psychiatry. 2003 Mar;60(3):238-43. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2005 Nov 30; [Epub ahead of print] Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt BA. The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull. 2003;29(4):717-28. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004 May 1;68(1):37-48. Malhotra AK, Murphy GM Jr, Kennedy JL, Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004 May;161(5):780-96. Malhotra AK. Candidate Gene Studies of Antipsychotic Drug Efficacy and Drug-Induced Weight Gain. Neurotox Res. 2004;6(1):51-6. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry. 2002 Apr;159:652-4. Miller R. & Mason, S. Diagnosis: Schizophrenia. New York: Columbia University Press, 2003. Miller R, Caponi J, Sevy S, Robinson D. The insight-adherence-abstinence triad: An integrated treatment focus for cannabis using first episode schizophrenia patients. Bulletin of the Menninger Clinic, 2005 69, 3, 220-236. Miller R, Mason, S.E. Cognitive enhancement therapy: A therapeutic treatment strategy for first-episode schizophrenia patients. Bulletin of the Menninger Clinic, 2004 68, 3, 213-230. Miller R, Mason S. Shame and Guilt in First Episode Schizophrenia. Contemporary Psychotherapy, 2005 35,2, 211-221. Narr KL, Bilder RM, Kim S, Thompson PM, Szeszko P, Robinson D, Luders E, Toga AW. Abnormal gyral complexity in first-episode schizophrenia. Biol Psychiatry. 2004 Apr 15;55(8):859-67. Narr KL, Thompson PM, Szeszko P, Robinson D, Jang S, Woods RP, Kim S, Hayashi KM, Asunction D, Toga AW, Bilder RM. Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage. 2004 Apr;21(4):1563-75. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002 Oct 1;57(2-3):209-19. Robinson DG, Woerner MG, Delman HM, Kane JM Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005 Jul;31(3):705-22. Epub 2005 Jul 8. Review. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004 Mar;161(3):473-9. Sevy S, Kay SR, Opler L, van Praag HM. Significance of cocaine history in schizophrenia. Journal of Nervous and Mental Disease. 1990; 178: 642-648. Sevy S, Nathanson K, Schechter C, Fulop G. Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia. Schizophrenia Bulletin. 2001; 27: 643-652. Sevy S, Robinson DG, Solloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance abuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica. 2001; 104:367-374. Sevy S, Kay Nathanson, Hema Visweswaraiah, Xavier Amador. The relationship between insight and symptoms in schizophrenia. Comprehensive Psychiatry. 2004; 45:16-19. Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswarajah H, Gunduz-Bruce H, Schooler, N. Double blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medication. Journal of Clinical Psychiatry. 2005; 66:839-843. Sircar R. Effect of melatonin on cocaine induced behavioral sensitization, Brain Research. 857: 295-299, 2000. Sircar R, Mallinson K, Goldbloom LM, Kehoe P. Postnatal stress selectively upregulates striatal NMDA receptors in male rats. Brain Research , 2001 904: 145-148. Sircar R, Soliman KFA. Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor, Pharmacology Biochemistry and Behavior, 2003 74: 943-952. Sircar R. Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-D-aspartate receptor upregulation, International Journal for Developmental Neuroscience, 2003 21: 159-167. Sircar R, Basak AK. Adolescent ?-hydroxybutyric acid exposure decreases cortical N-methyl-D-aspartate receptor and impairs spatial learning, Pharmacology, Biochemistry and Behavior, 2004 79: 701-708. Sircar R, Sircar D. Adolescent rats exposed to repeated ethanol treatment show lingering behavioral impairments, Accepted for publication in Alcoholism: Clinical and Experimental Research , 2005 29: 1402-1410. Smith GS, Lotrich FE, Malhotra AK, Lee AT, Ma Y, Kramer E, Gregersen PK, Eidelberg D, Pollock BG. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology. 2004 Dec;29(12):2226-34. Smith GS, Reynolds CF 3rd, Houck PR, Dew MA, Ma Y, Mulsant BH, Pollock BG. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):561-7. Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M, Larson J, Chaly T, Belakhleff A, Kramer E, Greenwald B, Kane JM, Laghrissi-Thode F, Pollock BG, Eidelber D. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse. 2002 Aug;45(2):105-12. Smith CW & Cornblatt B Attention deficits in the development of schizophrenia: Recent evidence from genetic high-risk and prodromal studies. Current Psychosis & Therapeutics Reports. 2005 3, 152-156. Szeszko PR, Ardekani BA, Ashtari M, Malhotra AK, Robinson DG, Bilder RM, Lim KO. White matter abnormalities in obsessive-compulsive disorder. Arch. Gen Psychiatry. 2005 Jul; 62(7):782-90. Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson D, Malhotra AK, Lencz T, Bates J, Cradall DT, Kane J M, Bilder RM. Smaller anterior hippocampal formation volume in antipsychotic-naïve patients with first-episode schizophrenia. Am J Psychiatry. 2003 Dec;160(12):2190-7. Szeszko PR, Ardekani BA, Ashtari M, Kumra S, Robinson DG, Sevy S, Gunduz-Bruce H, Malhotra AK, Kane JM, Bilder RM, Lim KO. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry. 2005 Mar;162(3):602-5. Szeszko PR, MacMillan S, McMeniman M, Chen S, Baribault K, Lim KO, Ivey J, Rose M, Banerjee SP, Bhandari R, Moore GJ, Rosenberg DR. Brain structural abnormalities in psychotropic drug-naive pediatric patients with obsessive-compulsive disorder. Am J Psychiatry. 2004 Jun;161(6):1049-56. Szeszko PR, Ardekani BA, Ashtari M, Malhotra AK, Robinson DG, Bilder RM, Lim KO. White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry. 2005 Jul;62(7):782-90. |
|
"Diagnosis: Schizophrenia"
Diagnosis: Schizophrenia, edited by Rachel Miller and Susan Mason, was published by Columbia University Press in 2003. It is written for patients who are in the early years of schizophrenia. Thirty-five patients enrolled in the First Episode Study participated in the design, writing, illustrating and editing of the book to help others experiencing schizophrenia for the first time cope with their life-changing condition. Contributions by Research psychiatrists Julia Becker M.D., Handan Gunduz-Bruce M.D, Anil Malhotra M.D., Alan Mendolowitz M.D. and Delbert Robinson M.D. provide the scientific perspective and data to make the book a comprehensive resource for learning and obtaining needed services for recovery. Diagnosis: Schizophrenia has also been placed on the New York State Statewide Curriculum for Social Work masters level education for evidence based practice in mental health.
Support for the book was provided by The Nicholas Family Charitable Trust.
|
